Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.77 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.74 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.74 |
| ▸ | LTA4H | P09960 | 2/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30876469 | 0.98 | HRH3 (0.74) | HRH3KEAP1NFE2L2LTA4HKCNH2 | |
| SCHEMBL19026551 | 0.91 | HRH3 (0.77) | HRH3KEAP1NFE2L2LTA4HTAAR1 | |
| SCHEMBL23291158 | 0.90 | HRH3 (0.63) | HRH3KEAP1NFE2L2LTA4HKCNH2 | |
| SCHEMBL874547 | 0.88 | HRH3 (0.70) | HRH3KEAP1NFE2L2LTA4HKCNH2 | |
| SCHEMBL928390 | 0.86 | HRH3 (0.77) | HRH3KEAP1NFE2L2LTA4HKCNH2 | |
| SCHEMBL110426 | 0.85 | KEAP1 (1.00) | HRH3KEAP1NFE2L2LTA4HKCNH2 | |
| SCHEMBL10662153 | 0.84 | HRH3 (0.77) | HRH3KEAP1NFE2L2LTA4HKCNH2 | |
| SCHEMBL4547156 | 0.84 | HRH3 (0.79) | HRH3KEAP1NFE2L2LTA4HKCNH2 | |
| Hydrochloric Acid SCHEMBL5803566 | 0.84 | KEAP1 (0.96) | HRH3KEAP1NFE2L2LTA4HKCNH2 | |
| SCHEMBL3973648 | 0.83 | CYP1A2 (0.62) | HRH3KEAP1NFE2L2LTA4HKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3814356-B1 | TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS | ZHEJIANG VIMGREEN PHARMACEUTICALS LTD (CN) | 2026-03-11 | — | — | EP | disclosed |
| WO-2024089155-A1 | HETEROCYCLIC COMPOUNDS AS STING ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-05-02 | — | — | WO | disclosed |
| US-11845751-B2 | Triazolotriazine derivatives as A2A receptor antagonists | ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) | 2023-12-19 | — | — | US | disclosed |
| US-11845751-B2 | Triazolotriazine derivatives as A2A receptor antagonists | ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) | 2023-12-19 | — | — | US | disclosed |
| US-11845751-B2 | Triazolotriazine derivatives as A2A receptor antagonists | ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) | 2023-12-19 | — | — | US | disclosed |
| CN-111051309-B | Triazolotriazine derivatives useful as A2A receptor antagonists | 浙江春禾医药科技有限公司 | 2023-05-26 | — | — | CN | disclosed |
| US-20210332055-A1 | TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS | ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) | 2021-10-28 | — | — | US | disclosed |
| US-20210332055-A1 | TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS | ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) | 2021-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11845751-B2 | Triazolotriazine derivatives as A2A receptor antagonists | ADORA2A, ADORA1, ADORA3 | HRH3 416/4885KEAP1 2134/4885NFE2L2 2638/4885 |
| US-20210332055-A1 | TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS | ADORA2A, ADORA1, ADORA3 | HRH3 416/4885KEAP1 2134/4885NFE2L2 2638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.